skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Structure of Hepatitis C virus envelope glycoprotein E1 antigenic site 314–324 in complex with antibody IGH526

Abstract

Hepatitis C virus (HCV) is a positive-strand RNA virus within the Flaviviridae family. The viral “spike” of HCV is formed by two envelope glycoproteins, E1 and E2, which together mediate viral entry by engaging host receptors and undergoing conformational changes to facilitate membrane fusion. While E2 can be readily produced in the absence of E1, E1 cannot be expressed without E2 and few reagents, including monoclonal antibodies, are available for study of this essential HCV glycoprotein. A human MAb to E1, IGH526, was previously reported to cross-neutralize different HCV isolates and, therefore, we sought to further characterize the IGH526 neutralizing epitope to obtain information for vaccine design. Here, we found that MAb IGH526 bound to a discontinuous epitope, but with a major component corresponding to E1 residues 314-324. The crystal structure of IGH526 Fab with this E1 glycopeptide at 1.75Å resolution revealed that the antibody binds to one face of an α-helical peptide. Single mutations on the helix substantially lowered IGH526 binding but did not affect neutralization, indicating either that multiple mutations are required or that additional regions are recognized by the antibody in the context of the membrane-associated envelope oligomer. Finally, molecular dynamics simulations indicate the free peptide ismore » flexible in solution, suggesting that it requires stabilization for use as a candidate vaccine immunogen.« less

Authors:
 [1];  [1];  [2];  [2];  [1];  [3];  [1];  [4];  [5];  [2]
  1. The Scripps Research Inst., La Jolla, CA (United States). Dept. of Integrative Structural and Computational Biology
  2. The Scripps Research Inst., La Jolla, CA (United States). Dept. of Immunology and Microbial Science
  3. The Scripps Research Inst., La Jolla, CA (United States). Dept. of Chemistry; The Scripps Research Inst., La Jolla, CA (United States). Dept. of Cell and Molecular Biology
  4. The Scripps Research Inst., La Jolla, CA (United States). Dept. of Chemistry; The Scripps Research Inst., La Jolla, CA (United States). Dept. of Cell and Molecular Biology
  5. The Scripps Research Inst., La Jolla, CA (United States). Dept. of Integrative Structural and Computational Biology; The Scripps Research Inst., La Jolla, CA (United States). Skaggs Inst. for Chemical Biology
Publication Date:
Research Org.:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Org.:
USDOE Office of Science (SC), Basic Energy Sciences (BES) (SC-22); National Institutes of Health (NIH)
OSTI Identifier:
1214858
Grant/Contract Number:
AC02-06CH11357; AI079031; AI106005; AI084817; U54 GM094586
Resource Type:
Journal Article: Accepted Manuscript
Journal Name:
Journal of Molecular Biology
Additional Journal Information:
Journal Volume: 427; Journal Issue: 16; Journal ID: ISSN 0022-2836
Publisher:
Elsevier
Country of Publication:
United States
Language:
ENGLISH
Subject:
59 BASIC BIOLOGICAL SCIENCES; 60 APPLIED LIFE SCIENCES; HCV; E1 envelope glycoprotein; IGH526; vaccine design

Citation Formats

Kong, Leopold, Kadam, Rameshwar U., Giang, Erick, Ruwona, Tinashe B., Nieusma, Travis, Culhane, Jeffrey C., Stanfield, Robyn L., Dawson, Philip E., Wilson, Ian A., and Law, Mansun. Structure of Hepatitis C virus envelope glycoprotein E1 antigenic site 314–324 in complex with antibody IGH526. United States: N. p., 2015. Web. doi:10.1016/j.jmb.2015.06.012.
Kong, Leopold, Kadam, Rameshwar U., Giang, Erick, Ruwona, Tinashe B., Nieusma, Travis, Culhane, Jeffrey C., Stanfield, Robyn L., Dawson, Philip E., Wilson, Ian A., & Law, Mansun. Structure of Hepatitis C virus envelope glycoprotein E1 antigenic site 314–324 in complex with antibody IGH526. United States. doi:10.1016/j.jmb.2015.06.012.
Kong, Leopold, Kadam, Rameshwar U., Giang, Erick, Ruwona, Tinashe B., Nieusma, Travis, Culhane, Jeffrey C., Stanfield, Robyn L., Dawson, Philip E., Wilson, Ian A., and Law, Mansun. 2015. "Structure of Hepatitis C virus envelope glycoprotein E1 antigenic site 314–324 in complex with antibody IGH526". United States. doi:10.1016/j.jmb.2015.06.012. https://www.osti.gov/servlets/purl/1214858.
@article{osti_1214858,
title = {Structure of Hepatitis C virus envelope glycoprotein E1 antigenic site 314–324 in complex with antibody IGH526},
author = {Kong, Leopold and Kadam, Rameshwar U. and Giang, Erick and Ruwona, Tinashe B. and Nieusma, Travis and Culhane, Jeffrey C. and Stanfield, Robyn L. and Dawson, Philip E. and Wilson, Ian A. and Law, Mansun},
abstractNote = {Hepatitis C virus (HCV) is a positive-strand RNA virus within the Flaviviridae family. The viral “spike” of HCV is formed by two envelope glycoproteins, E1 and E2, which together mediate viral entry by engaging host receptors and undergoing conformational changes to facilitate membrane fusion. While E2 can be readily produced in the absence of E1, E1 cannot be expressed without E2 and few reagents, including monoclonal antibodies, are available for study of this essential HCV glycoprotein. A human MAb to E1, IGH526, was previously reported to cross-neutralize different HCV isolates and, therefore, we sought to further characterize the IGH526 neutralizing epitope to obtain information for vaccine design. Here, we found that MAb IGH526 bound to a discontinuous epitope, but with a major component corresponding to E1 residues 314-324. The crystal structure of IGH526 Fab with this E1 glycopeptide at 1.75Å resolution revealed that the antibody binds to one face of an α-helical peptide. Single mutations on the helix substantially lowered IGH526 binding but did not affect neutralization, indicating either that multiple mutations are required or that additional regions are recognized by the antibody in the context of the membrane-associated envelope oligomer. Finally, molecular dynamics simulations indicate the free peptide is flexible in solution, suggesting that it requires stabilization for use as a candidate vaccine immunogen.},
doi = {10.1016/j.jmb.2015.06.012},
journal = {Journal of Molecular Biology},
number = 16,
volume = 427,
place = {United States},
year = 2015,
month = 6
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record

Citation Metrics:
Cited by: 3works
Citation information provided by
Web of Science

Save / Share:
  • Cited by 3
  • Respiratory syncytial virus (RSV) is a major cause of pneumonia and bronchiolitis in infants and elderly people. Currently there is no effective vaccine against RSV, but passive prophylaxis with neutralizing antibodies reduces hospitalizations. To investigate the mechanism of antibody-mediated RSV neutralization, we undertook structure-function studies of monoclonal antibody 101F, which binds a linear epitope in the RSV fusion glycoprotein. Crystal structures of the 101F antigen-binding fragment in complex with peptides from the fusion glycoprotein defined both the extent of the linear epitope and the interactions of residues that are mutated in antibody escape variants. The structure allowed for modeling ofmore » 101F in complex with trimers of the fusion glycoprotein, and the resulting models suggested that 101F may contact additional surfaces located outside the linear epitope. This hypothesis was supported by surface plasmon resonance experiments that demonstrated 101F bound the peptide epitope {approx}16,000-fold more weakly than the fusion glycoprotein. The modeling also showed no substantial clashes between 101F and the fusion glycoprotein in either the pre- or postfusion state, and cell-based assays indicated that 101F neutralization was not associated with blocking virus attachment. Collectively, these results provide a structural basis for RSV neutralization by antibodies that target a major antigenic site on the fusion glycoprotein.« less
  • Hepatitis C virus (HCV), a Hepacivirus, is a major cause of viral hepatitis, liver cirrhosis, and hepatocellular carcinoma. HCV envelope glycoproteins E1 and E2 mediate fusion and entry into host cells and are the primary targets of the humoral immune response. The crystal structure of the E2 core bound to broadly neutralizing antibody AR3C at 2.65 angstroms reveals a compact architecture composed of a central immunoglobulin-fold β sandwich flanked by two additional protein layers. The CD81 receptor binding site was identified by electron microscopy and site-directed mutagenesis and overlaps with the AR3C epitope. The x-ray and electron microscopy E2 structuresmore » differ markedly from predictions of an extended, three-domain, class II fusion protein fold and therefore provide valuable information for HCV drug and vaccine design.« less